BIM Mediates EGFR Tyrosine Kinase Inhibitor-Induced Apoptosis in Lung Cancers with Oncogenic EGFR Mutations

PLoS Medicine ◽

10.1371/journal.pmed.0040315 ◽

2007 ◽

Vol 4 (10) ◽

pp. e315 ◽

Author(s):

Daniel B Costa ◽

Balázs Halmos ◽

Amit Kumar ◽

Susan T Schumer ◽

Mark S Huberman ◽

...

Keyword(s):

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitor ◽

Kinase Inhibitor ◽

Egfr Mutations ◽

Egfr Tyrosine Kinase Inhibitor ◽

Lung Cancers ◽

Egfr Tyrosine Kinase ◽

Induced Apoptosis

Download Full-text

Survival‑associated factors of first‑line EGFR‑tyrosine kinase inhibitor responders and non‑responders in lung adenocarcinoma patients with common EGFR mutations

Molecular and Clinical Oncology ◽

10.3892/mco.2018.1550 ◽

2018 ◽

Author(s):

Ming‑Szu Hung ◽

Yu‑Hung Fang ◽

Yu‑Ching Lin ◽

Jr‑Hau Lung ◽

Meng‑Jer Hsieh ◽

...

Keyword(s):

Tyrosine Kinase ◽

Lung Adenocarcinoma ◽

Tyrosine Kinase Inhibitor ◽

Associated Factors ◽

Kinase Inhibitor ◽

Egfr Mutations ◽

Egfr Tyrosine Kinase Inhibitor ◽

Egfr Tyrosine Kinase

Download Full-text

PUMA mediates EGFR tyrosine kinase inhibitor-induced apoptosis in head and neck cancer cells

Oncogene ◽

10.1038/onc.2009.108 ◽

2009 ◽

Vol 28 (24) ◽

pp. 2348-2357 ◽

Author(s):

Q Sun ◽

L Ming ◽

S M Thomas ◽

Y Wang ◽

Z G Chen ◽

...

Keyword(s):

Head And Neck Cancer ◽

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitor ◽

Head And Neck ◽

Cancer Cells ◽

Neck Cancer ◽

Kinase Inhibitor ◽

Egfr Tyrosine Kinase Inhibitor ◽

Egfr Tyrosine Kinase ◽

Induced Apoptosis

Download Full-text

TAS6417/CLN-081 Is a Pan-Mutation–Selective EGFR Tyrosine Kinase Inhibitor with a Broad Spectrum of Preclinical Activity against Clinically Relevant EGFR Mutations

Molecular Cancer Research ◽

10.1158/1541-7786.mcr-19-0419 ◽

2019 ◽

Vol 17 (11) ◽

pp. 2233-2243 ◽

Author(s):

Hibiki Udagawa ◽

Shinichi Hasako ◽

Akihiro Ohashi ◽

Rumi Fujioka ◽

Yumi Hakozaki ◽

...

Keyword(s):

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitor ◽

Broad Spectrum ◽

Kinase Inhibitor ◽

Egfr Mutations ◽

Egfr Tyrosine Kinase Inhibitor ◽

Egfr Tyrosine Kinase

Download Full-text

Osimertinib, an Irreversible Next-Generation EGFR Tyrosine Kinase Inhibitor, Exerts Antitumor Activity in Various Preclinical NSCLC Models Harboring the Uncommon EGFR Mutations G719X or L861Q or S768I

Molecular Cancer Therapeutics ◽

10.1158/1535-7163.mct-20-0103 ◽

2020 ◽

Vol 19 (11) ◽

pp. 2298-2307

Author(s):

Nicolas Floc'h ◽

Sangbin Lim ◽

Sue Bickerton ◽

Afshan Ahmed ◽

Jonathan Orme ◽

...

Keyword(s):

Antitumor Activity ◽

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitor ◽

Kinase Inhibitor ◽

Egfr Mutations ◽

Next Generation ◽

Egfr Tyrosine Kinase Inhibitor ◽

Egfr Tyrosine Kinase

Download Full-text

Local microwave ablation with continued EGFR tyrosine kinase inhibitor as a treatment strategy in advanced non-small cell lung cancers that developed extra-central nervous system oligoprogressive disease during EGFR tyrosine kinase inhibitor treatment

Medicine ◽

10.1097/md.0000000000003998 ◽

2016 ◽

Vol 95 (25) ◽

pp. e3998 ◽

Author(s):

Yang Ni ◽

Jingwang Bi ◽

Xin Ye ◽

Weijun Fan ◽

Guohua Yu ◽

...

Keyword(s):

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitor ◽

Microwave Ablation ◽

Kinase Inhibitor ◽

Small Cell Lung ◽

Egfr Tyrosine Kinase Inhibitor ◽

Lung Cancers ◽

Egfr Tyrosine Kinase ◽

Inhibitor Treatment

Download Full-text

Dual-agent molecular targeting of growth factor receptors in hepatocellular cancer: Combining anti-EGFR antibody with an EGFR tyrosine kinase inhibitor

Zeitschrift für Gastroenterologie ◽

10.1055/s-2005-920152 ◽

2005 ◽

Vol 43 (05) ◽

Author(s):

A Hüther ◽

M Höpfner ◽

D Schuppan ◽

H Scherübl

Keyword(s):

Growth Factor ◽

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitor ◽

Kinase Inhibitor ◽

Hepatocellular Cancer ◽

Growth Factor Receptors ◽

Molecular Targeting ◽

Egfr Tyrosine Kinase Inhibitor ◽

Egfr Tyrosine Kinase ◽

Download Full-text

Anlotinib Hydrochloride Combined With EGFR-Tyrosine Kinase Inhibitor (TKI) in Treating Advanced NSCLC Patients With Acquired Resistance to EGFR-TKI

Case Medical Research ◽

10.31525/ct1-nct04007835 ◽

2019 ◽

Author(s):

Keyword(s):

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitor ◽

Advanced Nsclc ◽

Kinase Inhibitor ◽

Acquired Resistance ◽

Egfr Tyrosine Kinase Inhibitor ◽

Egfr Tyrosine Kinase ◽

Nsclc Patients ◽

Download Full-text

O-247 Molecular mechanisms of sensitivity and resistance to the HER1/EGFR-tyrosine kinase inhibitor erlotinib (Tarceva™)

Lung Cancer ◽

10.1016/s0169-5002(03)91905-2 ◽

2003 ◽

Vol 41 ◽

pp. S72 ◽

Author(s):

Roman Perez-Soler ◽

Qun Dai ◽

Yi-He Ling ◽

Marie Lee ◽

Glenn Kroog ◽

...

Keyword(s):

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitor ◽

Molecular Mechanisms ◽

Kinase Inhibitor ◽

Egfr Tyrosine Kinase Inhibitor ◽

Egfr Tyrosine Kinase

Download Full-text

Pathway Analysis of Glioblastoma Tissue after Preoperative Treatment with the EGFR Tyrosine Kinase Inhibitor Gefitinib—A Phase II Trial

Molecular Cancer Therapeutics ◽

10.1158/1535-7163.mct-11-0048 ◽

2011 ◽

Vol 10 (6) ◽

pp. 1102-1112 ◽

Author(s):

Monika E. Hegi ◽

Annie-Claire Diserens ◽

Pierre Bady ◽

Yuta Kamoshima ◽

Mathilde C. M. Kouwenhoven ◽

...

Keyword(s):

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitor ◽

Phase Ii ◽

Pathway Analysis ◽

Kinase Inhibitor ◽

Phase Ii Trial ◽

Preoperative Treatment ◽

Egfr Tyrosine Kinase Inhibitor ◽

Egfr Tyrosine Kinase

Download Full-text

P3.01-073 TPX-0005 with an EGFR Tyrosine Kinase Inhibitor (TKI) Overcomes Innate Resistance in EGFR Mutant NSCLC

Journal of Thoracic Oncology ◽

10.1016/j.jtho.2017.09.1514 ◽

2017 ◽

Vol 12 (11) ◽

pp. S2230

Author(s):

R. Rosell ◽

N. Karachaliou ◽

J.J. Cui ◽

I. Chaib ◽

J. Berenguer ◽

...

Keyword(s):

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitor ◽

Kinase Inhibitor ◽

Egfr Tyrosine Kinase Inhibitor ◽

Innate Resistance ◽

Egfr Tyrosine Kinase ◽

Download Full-text